DeliverSpring Health宣布Onco 360被选为OJEEDA的合作伙伴

2024-05-20 19:54

BrightSpring Health Services (NASDAQ:BTSG) is proud that its Co., Onco360, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
The FDA-approved treatment is specifically used for patients six months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
LGG is the most common central nervous system tumor in children, representing 30% of pediatric brain tumors.
“At Onco360, we’re always looking for partnerships to advance groundbreaking treatment options for rare cancers. We’re proud to partner with Day One Biopharmaceuticals to become a specialty provider for OJEMDA,” said Benito Fernandez, CCO at Onco360.

More on BrightSpring Health Services